Evidence map›Paper›PMID 41317788›Full record

ArticleJournal of molecular biology2026

Synthetic Type III-E CRISPR-Cas Effectors for Programmable RNA-targeting.

Daniel J Brogan, Calvin P Lin, Elena Dalla Benetta, Tianqi Wang, Fangying Chen, Harry Li, Claire Lin, Elizabeth A Komives, Omar S Akbari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel J BroganSchool of Biological Sciences, Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093, USA.
Calvin P LinDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0309, USA.
Elena Dalla BenettaSchool of Biological Sciences, Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093, USA.
Tianqi WangSchool of Biological Sciences, Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093, USA.
Fangying ChenSchool of Biological Sciences, Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093, USA.
Harry LiDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0309, USA.
Claire LinSchool of Biological Sciences, Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093, USA.
Elizabeth A KomivesDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093-0309, USA. Electronic address: ekomives@ucsd.edu.
Omar S AkbariSchool of Biological Sciences, Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: oakbari@ucsd.edu.

Funding

Development of synthetic viral circuitry to regulate viruses in mosquito disease vectorsDP2AI152071 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AKBARI, OMAR SULTAN · 2019 to 2019
$2.4M
Development of synthetic gene drives using small moleculesR01GM132825 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI AKBARI, OMAR SULTAN, CHOUDHARY, AMIT · 2019 to 2022
$1.4M
Transcriptome engineering technologies for the development of antiviral effectors in mosquitoesR21AI149161 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AKBARI, OMAR SULTAN · 2020 to 2021
$434k
NIAID NIH HHS DP2 AI152071NIAID NIH HHS R21 AI149161NIGMS NIH HHS R01 GM132825
6 · The paper itself

Abstract

The recent discovery of the type III-E class of CRISPR-Cas effectors has reshaped our fundamental understanding of CRISPR-Cas evolution and classification. Type III-E effectors are composed of several Cas7-like domains and a single Cas11-like domain naturally fused together to create a single polypeptide capable of targeting and degrading RNA. Here we identified a novel type III-E-like effector composed of three Cas7 domains and a Cas1 domain which was not active but could be engineered into an active chimeric RNA-targeting Cas effector by domain additions and swaps from other type III-E effectors. The results reveal that various domains in type III-E effectors can be swapped for the equivalent domain from a different type III-E effector. Remarkably, the Cas1 domain located at the C-terminus of Cas7-1 could be swapped in place of the Cas11 domain located between the Cas7.1 and the Cas7.2 domains of DiCas7-11. The results reveal a new modality for engineering type III-E effectors from the blueprints found in nature.

Indexed as

CRISPR-Associated ProteinsCRISPR-Cas SystemsGene EditingRNAClustered Regularly Interspaced Short Palindromic RepeatsProtein DomainsCRISPR-Associated ProteinsRNACRISPR-Casprotein engineeringRNA knockdowntype III-E effectors

Identifiers

PMID41317788
PMCPMC13404073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.